Mergers & acquisitions
The cash and stock deal will provide AbbVie with a pipeline boost in new therapeutic areas and will also decrease the company’s long-term reliance on its cash cow, Humira.
“Bristol-Myers Squibb is committed to working with regulatory authorities around the world on the proposed combination with Celgene,” the company stated. “The company is focused on realizing the promise of the transaction, and is continuing to work to complete the transaction on a timely basis.”
A report about Amsterdam-based uniQure indicated it is looking at various options, including a potential sale. As a result, company stock jumped as much as 10% in premarket trading.
Pfizer said Array’s pipeline, which includes BRAF/MEK inhibitors, will strengthen its own oncology offerings and provide the opportunity for additional growth.
Under the terms of the deal, a Merck subsidiary is buying all outstanding shares of Tilos for a total of up to $773 million, including an upfront payment and various potential milestone payments.
Government agencies in the United States and U.K. are scrutinizing Roche’s planned acquisition of the gene therapy company.
In addition to the deals, Vertex announced a new genetic therapies research site in the Boston and a new head of genetic therapies.
Under the terms of the merger, existing Vical stockholders will own 40% of the combined company and Brickell shareholders will own 60%.
Help us identify the leading employers in the life science industry! We want to uncover who leads in key areas like diversity, culture, unique benefits and, of course, who are the 2019 Life Sciences Ideal Employers.
labfolder GmbH from Berlin and the cubuslab GmbH from Karlsruhe are merging.
PRESS RELEASES